Lundbeck to Acquire Alder BioPharmaceuticals – a Company Committed to Transforming Migraine Treatment and Prevention – in a Transaction Valued at up to USD 1.95 Billion Net of Cash
Enhances Lundbeck’s leading portfolio of brain disease therapies with Alder’s highly complementary intravenous (IV) therapy for migraine prevention, eptinezumab

ABOUT THE NEWSROOM

Here you will find media contacts, plus the latest news, stories and insights from Lundbeck US. Lundbeck is a global pharmaceutical company solely focused on the brain, and our 900+ U.S. employees are committed to improving the lives of people affected by psychiatric and neurological disorders.